Previous 10 | Next 10 |
The following slide deck was published by IDEAYA Biosciences, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: IDEAYA Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation
The following slide deck was published by IDEAYA Biosciences, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: IDEAYA Biosciences, Inc. 2021 Q4 - Results - Earnings Call Presentation
IDEAYA Biosciences press release (NASDAQ:IDYA): Q4 GAAP EPS of -$0.47 misses by $0.16. Revenue of $2.96M (-72.1% Y/Y) misses by $6.02M. For further details see: IDEAYA Biosciences GAAP EPS of -$0.47 misses by $0.16, revenue of $2.96M misses by $6.02M
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update PR Newswire - Strong balance sheet of ~$368 million cash, cash equivalents and marketable securities as of December 31, 2021 is anticipated to fund planned operations into 2025 ...
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data PR Newswire Observed preclinical complete suppression (~95-100%) of tumor SDMA in multiple MTAP-deleted patient derived xenograft (PDX) models across indications Interim IDE397 clinical data demonstrat...
Ideaya Biosciences (NASDAQ:IDYA) signed additional clinical trial collaboration and supply agreements with Pfizer (NYSE:PFE) to evaluate darovasertib and crizotinib combination therapy in a potential phase 2 trial in patients with metastatic uveal melanoma (MUM) and in a phase 1 stu...
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors PR Newswire SOUTH SAN FRANCISCO, Calif. , March 14, 2022 /PRNe...
IDEAYA Biosciences (NASDAQ: IDYA) is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying ...
Stifel has upgraded Ideaya Biosciences (IDYA +5.9%) to buy from hold as the risk/reward for its lead candidate IDE397 has improved and the stock is down recently. The firm reduced its target price to $20 from $27 (~56% upside based on Wednesday's close). Analyst Benjamin Burnett said that whi...
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update PR Newswire SOUTH SAN FRANCISCO, Calif. , March 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precis...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...